Q3 EPS Estimates for BioAge Labs Decreased by William Blair

Key Points

• William Blair has reduced its Q3 2025 earnings per share (EPS) estimate for BioAge Labs from ($0.36) to ($0.50), signaling a significant downgrade.
• Wall Street Zen has downgraded BioAge Labs shares from a "hold" rating to a "sell" rating.
• In recent trading, BioAge Labs stock opened at $4.33, reflecting a notable decline from its one-year high of $26.62.

BioAge Labs, Inc. (NASDAQ:BIOA - Free Report) - William Blair reduced their Q3 2025 earnings per share (EPS) estimates for BioAge Labs in a report released on Wednesday, August 6th. William Blair analyst A. Hsieh now anticipates that the company will post earnings of ($0.50) per share for the quarter, down from their previous forecast of ($0.36). William Blair also issued estimates for BioAge Labs' Q4 2025 earnings at ($0.49) EPS, FY2025 earnings at ($1.95) EPS, Q1 2026 earnings at ($0.49) EPS, Q2 2026 earnings at ($0.48) EPS, Q3 2026 earnings at ($0.48) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($1.92) EPS and FY2027 earnings at ($2.05) EPS.

Separately, Wall Street Zen downgraded shares of BioAge Labs from a "hold" rating to a "sell" rating in a report on Sunday, June 29th.

BioAge Labs Stock Up 0.2%

Shares of BioAge Labs stock opened at $4.33 on Monday. BioAge Labs has a one year low of $2.88 and a one year high of $26.62.

BioAge Labs (NASDAQ:BIOA - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.04).

Hedge Funds Weigh In On BioAge Labs

A number of large investors have recently added to or reduced their stakes in the company. Intech Investment Management LLC bought a new position in BioAge Labs in the second quarter worth about $60,000. Police & Firemen s Retirement System of New Jersey bought a new position in BioAge Labs in the second quarter worth about $27,000. Geode Capital Management LLC raised its holdings in BioAge Labs by 60.8% in the second quarter. Geode Capital Management LLC now owns 453,455 shares of the company's stock worth $1,873,000 after purchasing an additional 171,426 shares in the last quarter. Finally, Public Employees Retirement System of Ohio bought a new position in BioAge Labs in the second quarter worth about $57,000.

BioAge Labs Company Profile

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.